Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Leukemia, Myeloid

abstract

  • At the highest dose tested, AEG35156 knocks down its target and appears very effective when combined with chemotherapy in patients with AML refractory to a single induction regimen.

publication date

  • October 2009

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5073380

Digital Object Identifier (DOI)

  • 10.1200/JCO.2009.21.8172

PubMed ID

  • 19652057

Additional Document Info

start page

  • 4741

end page

  • 6

volume

  • 27

number

  • 28